External innovation holds the key for long-term growth
03/12/20 -"Despite the generic erosion of Somatuline, Ipsen is targeting +2-5% sales growth p.a. until FY24, driven by the maximisation of the value of Cabometyx, Onivyde, Palovarotene, Decapeptyl and Dysport ..."
Pages
52
Language
English
Published on
03/12/20
You may also be interested by these reports :
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...
21/11/25
Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...